LIVE

AGGREGATED External reporting by CNBC. This page summarizes the publisher's feed entry; the full article is on www.cnbc.com.

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

CNBC ·

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

READ THE ORIGINAL AT CNBC ↗ MORE FROM THIS SOURCE

RELATED REPORTING